

12(90)/2022/डीपी/एनपीपीए/डिबीजन-II  
भारत सरकार Government of India  
रसायन एवं उर्वरक मंत्रालय Ministry of Chemicals & Fertilizers  
औषध विभाग Department of Pharmaceuticals  
राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण National Pharmaceuticals Pricing Authority  
तीसरी/पांचवीमंजिल 3<sup>rd</sup>/5<sup>th</sup> Floor  
वाई.एम.सी.ए .सांस्कृतिककेंद्रबिल्डिंग  
YMCA Cultural Center Building  
1, जयसिंहरोड़, नयीदिल्ली -110001  
1, Jai Singh Road, N.Delhi – 110001  
दिनांक: 25.11.2022

**OFFICE MEMORANDUM**

**Subject: Fixation of Ceiling Prices for Scheduled formulations under Revised Schedule I (NLEM 2022) of DPCO 2013 notified vide S.O. No. 5249 (E) dated 11.11.2022.**

With reference to the above, all the concerned manufacturers / marketing companies are requested to furnish the Price to Retailer (PTR) and Moving Annual Turnover (MAT) in value terms for the month of July, 2022 in the format given in **Table 1**. The information may be furnished positively within 7 days from the Issue of this O.M. in respect of formulations mentioned in **Table 2** below for taking appropriate action for fixation of ceiling prices pursuant to the issue of Revised Schedule-I of DPCO, 2013.

**Table 1**

S.No.	Formulation	Brand	Composition & Strength	Dosage/Specific ation		Price to Retailer (PTR) for July, 2022	MAT* Sales Value as on July, 2022 (Rs.)
				Type	Size		
1.							
2.							
3.							
4.							

Please insert additional rows (if required).

\*Moving Annual Turnover (MAT) Sales (excluding taxes) for July, 2022 means total sales during August, 2021 to July, 2022.

**Table 2**

S.N.	NLEM, 2022 Section No.	Medicine	Dosage form(s) and strength(s)
1	6.4.2	Bedaquiline	Tablet100mg
2	7.1.6	Bendamustinehydrochloride	Injection 25 mg/ vial
3	23.5.1	Buprenorphine	Tablet(Sub-lingual)0.4mg
4	23.5.2	Buprenorphine (A) +Naloxone (B)	Tablet(Sub-lingual)0.4mg(A)+0.1mg(B)
5	23.5.2	Buprenorphine (A) +Naloxone (B)	Tablet(Sub-lingual)2mg(A)+0.5mg(B)
6	6.8.1	Daclatasvir	Tablet30mg
7	6.4.6	Delamanid	Tablet50mg
8	7.1.26	Irinotecan HCltrihydrate	Solutionforinjection20mg/mL
9	6.2.2.11	Phenoxymethyl penicillin	Tablet250mg
10	6.2.2.12	ProcaineBenzylpenicillin	Powder for injection1000mg(=1millionIU)
11	6.7.1.6	TenofovirDisproxilFumarate (A) +Lamivudine(B)+Dolutegravir(c)	Tablet300mg(A)+300mg(B)+50 mg(c)
12	6.6.2.1	Valganciclovir*	Powder for oral solution 50mg / mL

2. The above mentioned information may be furnished within the stipulated period so that the ceiling prices are fixed in a transparent manner.

This issued with the approval of competent Authority.

Yours faithfully,

**(Mahaveer Saini)**  
Deputy Director

Copy to:

Apex Pharma Associations i.e. IDMA, IPA, OPSS, FOPE, FICCI, ASSOCHAM, etc. for information and necessary action.